441 related articles for article (PubMed ID: 22416775)
21. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM; White LA; Kolesar JM
Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
23. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
24. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
25. Vorinostat in cutaneous T-cell lymphoma.
Duvic M; Vu J
Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
[TBL] [Abstract][Full Text] [Related]
26. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
27. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
31. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibitors in cancer care.
Tofilon PJ; Camphausen K
Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
[TBL] [Abstract][Full Text] [Related]
33. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
34. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
35. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Khan O; La Thangue NB
Nat Clin Pract Oncol; 2008 Dec; 5(12):714-26. PubMed ID: 18839006
[TBL] [Abstract][Full Text] [Related]
36. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors in lymphoma.
Copeland A; Buglio D; Younes A
Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
39. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
40. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]